MoneyWorks4Me

Granules India informs about press release

04 Aug 2023 Evaluate

Granules India has that it enclosed press release today titled ‘Granules Pharmaceuticals, Inc. Successfully Completes USFDA Postmarketing Adverse Drug Experience (PADE) Inspection with Zero Observations’.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1847.55
Dr. Reddys Labs. 1193.15
Cipla 1378.70
Lupin 2086.60
Zydus Lifesciences 1154.50
View more..